Is JAK2 V617F mutation more than a diagnostic index?. A meta-analysis of clinical outcomes in essential thrombocythemia

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 67-73

  Dahabreh, Issa J ^a,b   Zoi, Katerina ^a   Giannouli, Stavroula ^b   Zoi, Christine ^a,b   Loukopoulos, Dimitrios ^a   Voulgarelis, Michael ^b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Essential thrombocythemia; JAK2 V617F; Meta analysis; Systematic review; Thrombosis

Indexed keywords

JANUS KINASE 2;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; META ANALYSIS; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; POLYCYTHEMIA; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS;

CELL DIVISION; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MUTATION; POLYCYTHEMIA VERA; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL;

EID: 55049131023     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.06.006     Document Type: Article

References (52)

1. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
2. Dahabreh I.J., Giannouli S., Zoi C., Zoi K., Loukopoulos D., and Voulgarelis M. Hypereosinophilic syndrome: another face of Janus?. Leuk Res (2008)
3. Dahabreh I.J., Giannouli S., Zoi C., Zoi K., Voulgarelis M., and Moutsopoulos H.M. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore) 86 (2007) 344-354
4. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
5. Antonioli E., Guglielmelli P., Pancrazzi A., Bogani C., Verrucci M., Ponziani V., et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19 (2005) 1847-1849
6. Kittur J., Knudson R.A., Lasho T.L., Finke C.M., Gangat N., Wolanskyj A.P., et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109 (2007) 2279-2284
7. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
8. Bumm T.G., Elsea C., Corbin A.S., Loriaux M., Sherbenou D., Wood L., et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66 (2006) 11156-11165
9. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., and Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 (2006) 1652-1660
10. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
11. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
12. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
13. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
14. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
15. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58 (1963) 690-700
16. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
17. Dahabreh I. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 5 (2008) 112-116
18. Altman D.G., and Bland J.M. Interaction revisited: the difference between two estimates. BMJ 326 (2003) 219
19. Lau J., Ioannidis J.P., and Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 127 (1997) 820-826
20. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
21. Cheung B., Radia D., Pantelidis P., Yadegarfar G., and Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 132 (2006) 244-245
22. Horn T., Kremer M., Dechow T., Pfeifer W.M., Geist B., Perker M., et al. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. J Mol Diagn 8 (2006) 299-304
23. Heller P.G., Lev P.R., Salim J.P., Kornblihtt L.I., Goette N.P., Chazarreta C.D., et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 77 (2006) 210-216
24. Stevenson W.S., Hoyt R., Bell A., Guipponi M., Juneja S., Grigg A.P., et al. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology 38 (2006) 336-342
25. Ahn J.Y., Yoo S.J., Bang S.M., Park P.W., Seo Y.H., Shin D.B., et al. JAK2(V617F) mutation in Korean patients with essential thrombocythemia. Korean J Lab Med 27 (2007) 77-82
26. Alvarez-Larran A., Cervantes F., Bellosillo B., Giralt M., Julia A., Hernandez-Boluda J.C., et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 21 (2007) 1218-1223
27. Andrikovics H., Szilvasi A., Meggyesi N., Kiraly V., Halm G., Lueff S., et al. Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection. Orv Hetil 148 (2007) 203-210
28. Hsiao H.H., Yang M.Y., Liu Y.C., Lee C.P., Yang W.C., Liu T.C., et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 35 (2007) 1704-1707
29. Wolanskyj A.P., Lasho T.L., Schwager S.M., McClure R.F., Wadleigh M., Lee S.J., et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131 (2005) 208-213
30. Ohyashiki K., Aota Y., Akahane D., Gotoh A., and Ohyashiki J.H. JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 21 (2007) 1097-1099
31. Pemmaraju N., Moliterno A.R., Williams D.M., Rogers O., and Spivak J.L. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 21 (2007) 2210-2212
32. Rudzki Z., Sacha T., Stoj A., Czekalska S., Wojcik M., Skotnicki A.B., et al. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study. Int J Hematol 86 (2007) 130-136
33. Speletas M., Katodritou E., Daiou C., Mandala E., Papadakis E., Kioumi A., et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 31 (2007) 1053-1062
34. Toyama K., Karasawa M., Yamane A., Irisawa H., Yokohama A., Saitoh T., et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 139 (2007) 64-69
35. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110 (2007) 840-846
36. Antonioli E., Guglielmelli P., Poli G., Bogani C., Pancrazzi A., Longo G., et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93 (2008) 41-48
37. Sterne J.A., Gavaghan D., and Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53 (2000) 1119-1129
38. Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C.A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110 (2007) 1092-1097
39. Tefferi A., and Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008) 14-22
40. Barbui T., and Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 33 (2007) 321-329
41. Tefferi A., and Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33 (2007) 313-320
42. Dupont S., Masse A., James C., Teyssandier I., Lecluse Y., Larbret F., et al. The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110 (2007) 1013-1021
43. Jamieson C.H., Gotlib J., Durocher J.A., Chao M.P., Mariappan M.R., Lay M., et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 103 (2006) 6224-6229
44. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109 (2007) 2310-2313
45. Tefferi A., Gangat N., and Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 109 (2007) 4105
46. Falanga A., Marchetti M., Vignoli A., Balducci D., Russo L., Guerini V., et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35 (2007) 702-711
47. Falanga A., Marchetti M., Evangelista V., Vignoli A., Licini M., Balicco M., et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96 (2000) 4261-4266
48. Arellano-Rodrigo E., Alvarez-Larran A., Reverter J.C., Villamor N., Colomer D., and Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91 (2006) 169-175
49. McIntyre T.M., Prescott S.M., Weyrich A.S., and Zimmerman G.A. Cell-cell interactions: leukocyte-endothelial interactions. Curr Opin Hematol 10 (2003) 150-158
50. Harrison C.N., Campbell P.J., Buck G., Wheatley K., East C.L., Bareford D., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353 (2005) 33-45
51. Barbui T., and Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 353 (2005) 85-86
52. Maugeri N., Giordano G., Petrilli M.P., Fraticelli V., de Gaetano G., Cerletti C., et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?. J Thromb Haemost 4 (2006) 2593-2598